Apps for People With Rheumatoid Arthritis to Monitor Their Disease Activity: A Review of Apps for Best Practice and Quality
Apps for People With Rheumatoid Arthritis to Monitor Their Disease Activity: A Review of Apps for Best Practice and Quality
复制标题
DOI：
10.2196/mhealth.6956
复制
发表时间：
2017-02-01
影响因子：
5
通讯作者：
Taylor, William J.
中科院分区：
文献类型：
--
作者：
Grainger, Rebecca;Townsley, Hermaleigh;Taylor, William J.
背景资料：类风湿性关节炎（RA）是一种慢性炎症性关节炎，需要长期治疗并由风湿病学家定期监测，以达到良好的健康效果。由于RA患者可能希望通过智能手机应用程序来监测自己的疾病活动，因此了解应用程序的功能和质量非常重要，目的：我们的研究旨在评估应用程序的功能和质量，以帮助人们通过（1）总结可用的应用程序，特别是用于测量RA疾病活动的仪器;（2）与美国修辞学会和欧洲反修辞联盟的应用程序功能比较（ACR和EULAR）用于监测RA疾病活动的指南;和（3）使用移动的应用程序评级量表（MARS）对应用程序质量进行评级。使用新西兰iTunes和Google Play应用程序商店的系统搜索来识别可用于监测RA疾病活动的所有应用程序，RA患者这些应用程序由关键元数据和应用程序功能描述。通过确定应用程序是否包括经验证的复合疾病活动性指标的计算和记录结果以供将来检索，评价应用程序对临床实践中监测RA疾病活动性建议的依从性。结果：检索识别出Google Play商店中的721个应用程序和iTunes商店中的216个应用程序，其中19个独特的应用程序符合纳入标准（8个来自两个应用程序商店，8个iTunes和3个Google Play）。总共有14个应用程序包含至少一种经验证的测量RA疾病活动的工具; 11个允许用户输入关节计数的应用程序中有7个使用标准的28个肿胀和压痛关节计数; 8个应用程序包含至少一种ACR和EULAR推荐的RA复合疾病活动（CDA）测量; 10个应用程序包含数据存储和检索。只有一个应用程序，关节炎电源，包括RA CDA措施和跟踪数据，但这个应用程序不包括标准的28招标和肿胀关节计数。应用程序的总体MARS评分中位数为3.41/5。在MARS评分>= 4/5的6个应用程序中，只有1个应用程序包含ACR和EULAR认可的CDA评分;然而，该应用程序没有数据跟踪功能。结论：本次审查发现缺乏高质量的应用程序用于RA疾病活动的纵向评估。目前的应用程序分为两类：主要用于风湿病学家的简单计算器和用于RA患者的数据跟踪工具。后者没有统一使用经验证的工具或综合疾病活动措施收集数据。需要适当的高质量应用程序，供风湿病学家和患者共同管理RA。
Background: Rheumatoid arthritis (RA) is a chronic inflammatory arthritis requiring long-term treatment with regular monitoring by a rheumatologist to achieve good health outcomes. Since people with RA may wish to monitor their own disease activity with a smartphone app, it is important to understand the functions and quality of apps for this purpose.Objective: The aim of our study was to assess the features and quality of apps to assist people to monitor their RA disease activity by (1) summarizing the available apps, particularly the instruments used for measurement of RA disease activity; (2) comparing the app features with American College of Rheumatology and European League against Rheumatism (ACR and EULAR) guidelines for monitoring of RA disease activity; and (3) rating app quality with the Mobile App Rating Scale (MARS).Methods: Systematic searches of the New Zealand iTunes and Google Play app stores were used to identify all apps for monitoring of RA disease activity that could be used by people with RA. The apps were described by both key metadata and app functionality. App adherence with recommendations for monitoring of RA disease activity in clinical practice was evaluated by identifying whether apps included calculation of a validated composite disease activity measure and recorded results for future retrieval. App quality was assessed by 2 independent reviewers using the MARS.Results: The search identified 721 apps in the Google Play store and 216 in the iTunes store, of which 19 unique apps met criteria for inclusion (8 from both app stores, 8 iTunes, and 3 Google Play). In total, 14 apps included at least one validated instrument measuring RA disease activity; 7 of 11 apps that allowed users to enter a joint count used the standard 28 swollen and tender joint count; 8 apps included at least one ACR and EULAR-recommended RA composite disease activity (CDA) measure; and 10 apps included data storage and retrieval. Only 1 app, Arthritis Power, included both an RA CDA measure and tracked data, but this app did not include the standard 28 tender and swollen joint count. The median overall MARS score for apps was 3.41/5. Of the 6 apps that scored >= 4/5 on the overall MARS rating, only 1 included a CDA score endorsed by ACR and EULAR; however, this app did not have a data tracking function.Conclusions: This review found a lack of high-quality apps for longitudinal assessment of RA disease activity. Current apps fall into two categories: simple calculators primarily for rheumatologists and data tracking tools for people with RA. The latter do not uniformly collect data using validated instruments or composite disease activity measures. There is a need for appropriate, high-quality apps for use by rheumatologists and patients together in co-management of RA.